Filing Details

Accession Number:
0000899243-18-011871
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-05-08 16:57:19
Reporting Period:
2018-05-04
Accepted Time:
2018-05-08 16:57:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1597264 Blueprint Medicines Corp BPMC () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1319446 Alexis Borisy C/O Third Rock Ventures, Llc,
29 Newbury Street, 3Rd Floor
Boston MA 02116
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-05-04 0 $0.00 0 No 4 S Indirect See Footnote
Common Stock Disposition 2018-05-07 0 $0.00 0 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 53,249 Direct
Footnotes
  1. On May 4, 2018, Third Rock Ventures II, L.P. ("TRV II") sold (i) 130,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $78.35 to $79.12, inclusive, at a weighted average price per share of $78.9148 and (ii) 20,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $79.40 to $79.80, inclusive, at a weighted average price per share of $79.4912. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).
  2. After the above transaction, TRV II owned 2,303,753 shares of Common Stock of the Issuer.
  3. The reporting person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of the TRV II. The reporting person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
  4. On May 7, 2018, TRV II sold (i) 284,378 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $78.10 to $79.07, inclusive, at a weighted average price per share of $78.5484 and (ii) 33,122 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $79.12 to $79.57, inclusive, at a weighted average price per share of $79.3597. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).
  5. After the above transaction, TRV II owned 1,986,253 shares of Common Stock of the Issuer.